This indicates that increasing pancreatitis risk in ITP patients may be related to platelet-derived microparticles and the loss of platelet surface GPIIb/IIIa due to an anti-GPIIb/IIIa antibody effect. This evidence concerns the gene ITGA2B and autoimmune thrombocytopenic purpura.